Pathway Therapeutics' Series B Round

Pathway Therapeutics raised a round of funding on May 31, 2011.

Pathway Therapeutics is a clinical stage, privately held, pharmaceutical company developing differentiated isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory dise…

Articles about Pathway Therapeutics' Series B Round: